Gleiss Lutz advises investor on Series A round of financing for BioNTech
Gleiss Lutz has advised one of the investors involved in the Series A round of financing for biotechnology company BioNTech. The Series A round totalling 270 million US dollars was led by the Redmile Group as the main investor in this round of financing and joined by Janus Henderson Investors, Invus, Fidelity Management & Research Company and several European family offices. The Struengmann Family Office, an existing majority shareholder in BioNTech, also participated in the financing.
BioNTech AG is Europe's largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing.
BioNTech will use the capital to further advance its clinical pipeline of individualized immunotherapies.
The investor was advised by Dr. Martin Viciano Gofferje (partner, lead) and Dr. Micha Pfarr (both corporate/M&A, both Berlin).